The need for the GREAT+ score to predict relapse in Graves' disease: a questionnaire among patients and internal medicine specialists.

ABSTRACT:

Purpose

Graves' disease (GD) is an auto-immune cause of hyperthyroidism. First-line treatment often consists of a 12-18 month course of antithyroid drugs (ATD). After discontinuation of ATD, GD relapses in approximately 50% of patients. The 'Graves recurrent event after therapy+ ' (GREAT+) score may predict individual relapse chances after ATD discontinuation more accurately based on clinical and laboratory parameters at diagnosis. We investigated the need for the GREAT+ score through an online questionnaire among GD patients and physicians treating GD.

Methods

An anonymous online questionnaire was distributed to patients and physicians between June 2022 and August 2023.

Results

The questionnaire was completed by 532 patients and 44 physicians. Results showed that 94%

SUBMITTER: Jansen HI 

PROVIDER: S-EPMC11393202 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature